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without comorbid depression in the US in 2001. METHODS:
Retrospective case-control analysis was conducted of the 2001
Medical Expenditure Panel Survey. In 2001, 32,122 persons
from the US civilian noninstitutionalized population were sur-
veyed. A total of 1101 patients 18 years or older with chronic
obstructive pulmonary disease were identiﬁed. Cases and con-
trols were identiﬁed using ICD-9 codes. The data contained 153
cases with chronic obstructive pulmonary disease and depression
and 948 similar patients without comorbid depression. Cases
were matched at a 1 :1 ratio to controls based on age, race,
gender, and number of comorbidities apart from depression. 
The matching procedure resulted in 145 pairs. Sample estimates
were projected to the population. Expenditure variables repre-
sent sums of all annual out-of-pocket expenditures and third
party payments. Differences in resource use and expenditures
between cases and controls were examined using t-tests. Data
were analyzed using SAS Version 8.2. RESULTS: Patients with
chronic obstructive pulmonary disease and comorbid depression
had higher average total health care expenditures ($10,845 vs.
$6,430; p = 0.0231), expenditures for prescription medications
($2,643 vs. $1574; p = 0.0007), use of ofﬁce-based visits (15.5
vs. 9.4; p = 0.0027), and number of annual prescription med-
ications purchased (45.8 vs. 27.9; p = 0.0001) than the control
group. Net incremental expenditures associated with comorbid
depression were $7,030,575,677 for total health care and
$1,698,632,604 for prescription medications. CONCLUSIONS:
Total health care expenditures were 1.7 times higher for patients
with chronic obstructive pulmonary disease and comorbid
depression than for similar patients without depression matched
on age, gender, race, and number of comorbidities. Depression
in conjunction with chronic obstructive pulmonary is associated
with considerable health care expenditures and utilization of
ofﬁce-based services and prescription medications.
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OBJECTIVES: The prevalence of chronic obstructive pulmonary
disease (COPD) in Hong Kong has been estimated to be 0.35 per
1000 population. The cost of management can therefore trans-
late into an enormous burden on the health care budget. Current
pharmacotherapy includes bronchodilators plus anticholinergics.
Patient compliance can be a problem due to multiple daily
dosing, hence the present study aims to evaluate the potential
beneﬁts of tiotropium with once-daily dosage. METHODS: The
cost of management of COPD was estimated by retrospective
review of the history of a cohort of COPD patients admitted to
the Prince of Wales Hospital (PWH) in Hong Kong from January
1, 2001 to December 31, 2001. Cost items included hospital-
ization, procedures, laboratory tests, medications and outpatient
clinic visits. The cost-effectiveness (CE) model for COPD devel-
oped by Boehringer-Ingelheim was used to assess the CE of
COPD therapies. All analysis was based on local cost data, and
probabilities of events and efﬁcacy data of tiotropium were
adopted from overseas published randomized controlled trials as
there is yet no local published data. The study was performed
from the perspective of a public hospital. RESULTS: Data of 30
patients admitted to the PWH due to COPD were analyzed with
the model. Compared to ipratropium, the once-daily dosage of
tiotropium showed a decrease in number of exacerbations (0.89
vs. 1.21), a decrease in the management cost due to exacerba-
tions (US$2550 vs. 4183) and the cost per exacerbation avoided
due to tiotropium was US$4278. CONCLUSION: Based on 
our preliminary results, tiotropium appears to be a more cost-
effective agent in the treatment of COPD when compared to
ipratropium.
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OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is
a major cause of death and disability throughout the world. The
objective of this study was to evaluate the health/economics 
consequence of four treatments (tiotropium, ipratropium, sal-
meterol and usual care) for patients with COPD in Japan.
METHODS: In order to estimate the patient’s prognosis for one
year, we constructed a Markov model based on the model devel-
oped by Oosenbrink J et al. in Netherlands. Three Markov stages
were set based on the degree of patient’s symptoms, e.g., mod-
erate, severe, and very severe. Acute exacerbation was also
included in the model. Transition probabilities were derived from
several clinical trials. The duration of remaining in the moder-
ate stage was used to deﬁne effectiveness. This study was con-
ducted from the payer’s perspective and only direct medical costs 
were considered. Since the time horizon was one year, discount-
ing was not considered. RESULTS: The expected costs for
tiotropium, ipratropium, salmeterol and usual care were
JPY559,314, JPY771,395, JPY612,707 and JPY621,400, respec-
tively ($1 = JPY103.84). The periods of duration of remaining
in the moderate stage (months) were 8.09, 5.56, 6.99 and 6.43,
respectively. The numbers of acute exacerbation were 0.80, 1.19,
0.96 and 0.91, respectively. A sensitivity analysis on the proba-
bility of home oxygen therapy during maintenance therapy also
showed that the tiotropium was the most cost-effective treat-
ment. CONCLUSION: In spite of the highest daily drug cost,
tiotropium is a cost-saving therapy for treatment of COPD
patients in Japan.
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OBJECTIVES: Most adherence studies have focused on oral
medications, with less attention on diseases where non-oral
routes of administration are predominant. Our objective was to
estimate adherence in VA patients using medications for chronic
respiratory disease and examine factors related to adherence.
METHODS: We identiﬁed patients treated at Chicago-area VAs
that ﬁlled at least two respiratory medications between 08/2002
and 07/2003 (baseline period). We calculated medication pos-
session ratios (MPRs) for each class of respiratory medication
between 08/2003 and 07/2004 (study period) that patients ﬁlled
during the baseline period. Patients were classiﬁed as having
asthma, COPD, combined asthma and COPD (CAC) or none
based on diagnoses at baseline. Average MPR for each medica-
tion category was calculated and logistic regression was used to
identify factors associated with MPRs of >= 75%. RESULTS:
There were 7511 patients included (96.7% male, 35% white).
The number of patients by disease were: COPD = 3721 (49.5%);
asthma = 1045 (13.9%); CAC = 726 (9.7%) and none = 2019
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(26.9%). Overall, MPRs were 0.58 for long-acting beta-agonists
(LABA); 0.61 for ipratropium+short-acting beta-agonist; 0.63
for ipratropium; 0.63 for inhaled corticosteroids (ICS); and 0.90
for theophylline (THEO). There were similar results in stratiﬁed
analyses by disease group with lowest MPRs for LABA and
highest for THEO. For ICS users, factors associated with MPRs
>= 0.75 were: higher proportion of prescriptions through mail
order, Caucasians, and ED visit or hospitalization in the baseline
period. For LABA users, in addition to the factors for ICS users,
specialist provider visits were associated with high MPRs. CON-
CLUSIONS: Patients had higher levels of adherence for oral
medications than for inhaled medications. Higher adherence
rates were associated with serious events and greater use of mail
order. Thus, route of administration, disease and health system
factors all appear to inﬂuence adherence to chronic respiratory
medications.
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OBJECTIVE: This study examines the predictors of patient per-
sistency for major drug categories related to the treatment of
Asthma and COPD. METHODS: The study design was retro-
spective covering the 12-month, longitudinal period (October
2003–September 2004). It included analysis of electronic
CMS1500 claims for 26,152 unique patients (HIPAA compli-
ant). Patients’ medication was assessed through NCPDP elec-
tronic claims utilizing NDC codes and drug classes. Treatment
persistency was identiﬁed and compared across drugs in each
disease group. Analysis included calculations of descriptive sta-
tistics and regression modeling. RESULTS: On average, COPD
patients are more persistent then asthma patients. In particular,
the persistency of COPD patients taking Advair, Combivent,
Flovent and Pulmicort was higher then those patients diagnosed
with asthma, respectively by 13.5%, 34.3%, 25.8% and 34.6%
(P < 0.05). The age of patients is one of the most important pre-
dictors of a patients’ persistency. For example, the likelihood of
reﬁlling a long-acting bronchodilator (LABA) prescription for
asthma in patients age 18 years and older is 1.51 times higher
(p < 0.05) than for those patients who are in the age category
17 years and younger. For both, asthma and COPD, there is a
strong relationship between therapeutic class of drugs and per-
sistency. The highest persistency of asthma patients was identi-
ﬁed for those who use xanthines, and the lowest for those who
take oral beta-blockers (1.89 times difference, P < 0.05). COPD
patients were more persistent in their use of xanthines and had
their lowest persistency on inhaled corticosteroids (1.66 times
difference, P < 0.05). Logistic regression models were created to
quantify the relationship between annual average lengths of
treatment and predictors. CONCLUSIONS: There is a signiﬁ-
cant difference between drug persistency for patients with
asthma and COPD even when controlling for the same medica-
tion. Adjusted for diagnosis, the major predictors of patient 
persistency appeared to be patient’s age and therapeutic drug 
category.
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OBJECTIVE: To establish the need to include designated 
community (private) pharmacies/pharmacists in the Lagos State
DOTS programme for effective control of Tuberculosis.
METHOD: A cross sectional descriptive study involving the 
use of semi structured questionnaires administered to a random
sample of an estimated population(150) of community pharma-
cists in Lagos State of Nigeria. Data was analysed by use of SPSS
12. RESULTS: The results show that: 86.8% of respondents
stocked anti-TB drugs; 67.2% of them had dispensed these drugs
at least within the immediate past one month preceding survey;
19.3% of them were patronised daily and 43.3% dispensed
without a doctors prescription. 63.7% of respondents did not
acknowledge that TB drugs were given to patients free of charge
anywhere, 43.4% did not know about DOTS; 89.2% were of
the opinion that community pharmacies would help increase TB
control coverage, 68.1% would accept to render DOTS services
in their pharmacies out of which 15.5% would do that at no
costs. 80.9% of respondents claimed that a pharmacist is on 
duty in their pharmacies throughout open hours; however 
most were not seen until after several visits. 1.4% of the phar-
macists were of the opinion that TB is incurable while 8.3% 
said TB runs in families, however 75.8% reported that most 
HIV patients present with TB co-infection. CONCLUSION:
Designated community pharmacies that meet basic ethical
requirements with regards to environment, facilities, location
and personnel should be accredited to render DOTS services for
effective and efﬁcient grass root TB control, especially in places
like Nigeria where TB is on the increase as a result of HIV 
pandemic. This will improve proper monitoring and patients
compliance by reducing travel time, cost and risk of travel to
clinics, social stigmatisation, waiting time, and generally reduce
the real cost of treatment for patients, with an assured wider 
coverage.
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INTRODUCTION: This study identiﬁes important risk factors,
race and predictors of heart failure (HF) in a chronic obstructive
pulmonary disease (COPD) Medicaid population, to help inform
plans and better target interventions for COPD disease manage-
ment. METHODS: A retrospective analysis was performed for
all medical claims of Medicaid COPD patients, between January
1, 2001-December, 31, 2003. COPD patients were included if
they had at least one claim with ICD-9 codes 491.xx, 4922.xx,
or 496.xx, in the primary, secondary or tertiary diagnosis. We
used multivariate logistic regression models to evaluate associa-
tions between heart failure and race, adjusting for age, gender,
cardiovascular diseases and risk factors. RESULTS: Total of
13,924 COPD patients, mean age 42. African Americans (OR =
1.25 p = 0.0001 CI 1.12–1.40) were more likely to have HF than
others during their follow up, even after adjusting for age, gender
and clinical risk factors. Patients older than 60 (OR = 5.13 p <
0.0001 CI 4.16–6.32) and those between 40 and 60 (OR = 3.34
p < 0.0001 CI 2.75–4.05) were more likely to have HF than those
younger than 40. Hypertension (OR = 2.30 p < 0.0001 CI
2.02–2.61), diabetes (OR = 2.16 p < 0.0001 CI 1.93–2.42),
obesity (OR = 2.18 p < 0.0001 CI 1.91–2.48), acute myocardial
infarction (OR = 3.09 p < 0.0001 CI 2.56–3.73) and cardiomy-
opathy (OR = 15.76 p < 0.0001 CI 12.95–19.18) were also sig-
niﬁcant predictors of heart failure. Gender and urban residence
